Compare Figs Inc (FIGS) vs Hims and Hers Health Inc (HIMS) Price & Performance

FIGS stock trades at $15.78, up 12.23% with strong technical momentum and bullish moving averages. The company shows accelerating revenue growth from $556M in 2024 to $631M in 2025, with net income improving to $34M. Recent Q2 2026 earnings beat expectations by 64%, and international sales surged 67% according to Zacks Research on August 20, 2026. The stock faces valuation concerns with a P/E of 45.39, but analyst consensus targets $18.00 representing 14% upside potential.

Outlook remains positive with projected 2026 revenue of $710M and net income of $62M, though rich valuation requires continued execution. Key risks include competitive pressures and margin sustainability. With 60% analyst buy ratings and improving cash flow projections, FIGS offers growth exposure but demands careful risk management given premium multiples.

Hims & Hers Health trades at $30.92, up 4.67% on the day, amid a bearish technical signal and significant legal headwinds from multiple securities class action lawsuits. The stock shows mixed fundamentals with strong revenue growth to $2.35 billion in 2025 but a sharp reversal to a net loss of -$142 million in 2026, reflecting profitability challenges. Valuation ratios appear elevated with a P/E of 57.14 and EV/EBITDA of 205.86, while analyst consensus remains cautiously optimistic with a $32.17 price target.

The outlook is clouded by legal risks and recent earnings misses, though the company's gross margin of 68.43% indicates underlying business strength. Investment opportunity hinges on resolving regulatory scrutiny and returning to profitability, but near-term volatility is likely. Key risks include the FTC lawsuit outcome and sustained negative cash flow, demanding careful risk assessment by investors.